How AI is Changing Clinical Development
AI is no longer a peripheral tool in drug development. It is reshaping how trials are designed, run, and completed, and the pace of change is accelerating. In this episode of the Drug Discovery World Podcast, Suzanne Caruso, President and General Manager of Clinical, Regulatory and Strategic Intelligence at Norstella, speaks with host Bruno Quinney […]
Rewriting the Clinical and Commercial Rulebook with Real-World Data
This webinar explores how real-world data (RWD) and AI are transforming clinical development, evidence generation, and commercialization, particularly in rare diseases and brain cancer. Speakers discuss how integrated RWD helps identify geographically dispersed patients, optimize trial design, support biomarker-driven targeting, and improve commercial strategy, while AI and NLP enable deeper analysis of unstructured clinical data […]
Trustworthy and Novel AI in Clinical Trial Planning
This pharmaphorum podcast explores how AI is transforming drug development and commercialization, with Norstella Chief Product Officer Kris Kaneta discussing the growing role of clinical AI powered by robust patient-level data. Kaneta explains how AI can move beyond administrative efficiency to deliver real strategic recommendations for clinical trials, commercialization and decision-making across the product lifecycle. […]
Why an AI-Native Biotech Chose Norstella
Drug development has made huge scientific progress over the last decade. The way we run clinical development has changed far less. Timelines are still long. Costs are still high. And most of the risk is decided before a trial even begins—we just don’t treat it that way. Teams are making critical decisions about study design, […]
Norstella and Replit Team Up to Accelerate Innovation and Optimize Commercial Processes with AI
Innovation at Norstella often begins with a question: What if we could move faster—without sacrificing quality or compliance? During a recent hackathon, Norstella’s commercial and product teams had a chance to answer that question firsthand and help us drive our mission of improving patient access to lifesaving therapies across the drug development cycle by using […]
The Convergence of AI and Real-World Data are Reshaping Clinical Trials
As clinical trials increase in number and complexity, so does the competition for the patients best aligned to the study requirements. And with clinical trial processes relatively unchanged over the past decades, a patient and investigator bottleneck has emerged. Finally, with the convergence of artificial intelligence and algorithms trained on real-world data (RWD) sources, we […]
The R&D Implications of Market Access Complexity
Our latest research strongly suggests that a highly dynamic market access situation in the US is feeding back into upstream decisions around R&D strategy. We explored this topic in detail in a recent white paper called Working Backwards: Patient access strategy is now guiding R&D. This article briefly summarizes the first half of the report. […]
The New Mandate: How Diversity in Clinical Trials is Evolving From Ideal to Imperative
There are roughly 8.2 billion people on the planet—each with a unique genetic makeup and lived experience. Imagine how much stronger science could be if clinical trials embraced that full spectrum. In recent years, the call for greater diversity in clinical trials has grown louder. Once treated as a “nice to have,” inclusivity in medical […]
The Patient Availability Conundrum
Despite tremendous scientific and medical advances, the economics of investing in drug research and development are challenging. The long-term trend suggests increasing R&D costs, lengthy development timelines, and high rates of failure. There are many factors that influence a positive outcome, from individual drug development decisions up to wider regulatory frameworks, all of which are […]
Biopharma’s R&D Engine and the Importance of Looking East
One of the main topics of conversation at the beginning of 2025 is how pharma companies should build their pipelines and the rising role that China is playing. A widely-cited report from Stifel showed that 30% of large pharma’s licensing deals now involve a Chinese biotech. This shows the growing interest in partnering in the […]
